A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2006
12/21/2006	WO2006133533A1 A treatment for short bowel syndrome
12/21/2006	WO2006133486A1 CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTOR:Fc COMPLEXES AND USES THEREOF
12/21/2006	WO2006133477A1 Peptides corresponding to human growth hormone
12/21/2006	WO2006113599A3 Methods of diagnosing inflammatory diseases of intestine
12/21/2006	WO2006113347A3 Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products
12/21/2006	WO2006110623A3 Targeted cholera toxin for treatment of persistent or chonic pain
12/21/2006	WO2006109044A3 Selective modulation of tumour necrosis factor receptors in therapy
12/21/2006	WO2006108718B1 Micro rna
12/21/2006	WO2006108686A3 Bnp agonists
12/21/2006	WO2006106311A3 Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
12/21/2006	WO2006101910A3 Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
12/21/2006	WO2006101909A3 Combination therapy for treating or preventing diseases
12/21/2006	WO2006100430A3 Polypeptides
12/21/2006	WO2006097793A3 Compositions capable of facilitating penetration across a biological barrier
12/21/2006	WO2006097732A3 Treatment of autoimmune and inflammatory diseases
12/21/2006	WO2006097725A3 Pharmaceutical compositions comprising microparticles for delivery into neurons
12/21/2006	WO2006091773A3 Compositions and methods related to serpin spi6
12/21/2006	WO2006089005A3 Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
12/21/2006	WO2006087533A3 Ricin-binding peptides and methods for use thereof
12/21/2006	WO2006086544A3 Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
12/21/2006	WO2006085121A3 Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
12/21/2006	WO2006084145A3 Methods of using il-1 antagonists to reduce c-reactive protein
12/21/2006	WO2006079790A3 Controlled production and delivery of biologically active agents by gut bacteria
12/21/2006	WO2006079019A3 Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
12/21/2006	WO2006078899A3 Mucin hypersecretion inhibitors based on the structure of mans and methods of use
12/21/2006	WO2006071796A3 Pulmonary surfactant formulations
12/21/2006	WO2006066083A3 Peptide-enhanced corneal drug delivery
12/21/2006	WO2006060473A3 Methods of treatment of injured or diseased joints with lubricin compositions
12/21/2006	WO2006050959A3 Molecules which promote hematopoiesis
12/21/2006	WO2006042112A3 Aptamer regulated nucleic acids and uses thereof
12/21/2006	WO2006036371A3 Combination therapy
12/21/2006	WO2006014999A3 Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
12/21/2006	WO2006010155A3 Gonadotropin releasing hormone antagonists
12/21/2006	WO2005121172A8 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
12/21/2006	WO2005115367A3 Modulation of neurotransmitter activity in neurons
12/21/2006	WO2005070444A3 Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
12/21/2006	WO2005062967A3 Novel anti-il 13 antibodies and uses thereof
12/21/2006	WO2005037193A3 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
12/21/2006	WO2005018535A3 Compositions and methods for treatment of severe acute respiratory syndrome (sars)
12/21/2006	WO2005016127A3 Prion-specific peptide reagents
12/21/2006	WO2004041172A3 Interferon antagonists useful for the treatment of interferon related diseases
12/21/2006	WO2004020578A3 Glycosylation modified il-20
12/21/2006	WO2003054144A3 Human ras interacting protein
12/21/2006	US20060288434 Inhibiting angiogenesis in a mammal by administering an antibody which specifically binds to EphriniB2 or EphB4; cardiovascular disorders
12/21/2006	US20060287513 Compositions and methods for the therapy and diagnosis of breast cancer
12/21/2006	US20060287510 Crystallization of IGF-1
12/21/2006	US20060287509 isolated nucleic acid encoding a human antibody that specifically binds to C-ERBB-2 protein product of HER2/NEU oncogene; for diagnosis of cancer/tumors which over express this gene; for immunotoxins and other antitumor/anticarcinogenic agents; less immunogenic
12/21/2006	US20060287504 Universal procedure for refolding recombinant proteins
12/21/2006	US20060287502 C3b/C4b complement receptor-like molecules and uses thereof
12/21/2006	US20060287396 4-aryl quinols and analogs thereof as therapeutic agents
12/21/2006	US20060287367 Pyridoxamine for the treatment of diabetic kidney disease
12/21/2006	US20060287314 2-amino-4-morpholino-6-(4-acetanilide)pteridine; 2-amino-4-morpholino-6-(4-benzoylaminophenyl)pteridine; 2-amino-4-morpholino-6-(4-methylsulfonylaminophenyl)pteridine; 2-amino-4-morpholino-6-[3-Boc-(L)-phenylalanine-aminophenyl]pteridine; immunosuppressive; transplant rejection; antiinflammatory
12/21/2006	US20060287306 Compounds to treat alzheimer's disease
12/21/2006	US20060287274 Phosphoepoxides, method for making same and uses
12/21/2006	US20060287268 Splice-region antisense composition and method
12/21/2006	US20060287266 Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability
12/21/2006	US20060287258 administering to the female an antibody that reduces the effect of prokineticin 1 on a prokineticin receptor to treat endometriosis; gonadotropin releasing hormone (GnRH) antagonist is selected from teverelix, abarelix, cetroelix or ganirelix antagonises the estrogen receptor
12/21/2006	US20060287252 Substances k01-0509 and process for producing the same
12/21/2006	US20060287251 Combination therapy for glycaemic control
12/21/2006	US20060287250 Intermediates: omega(1-haloalkoxycarbonylamino)alkanoates, e.g., Benzyl 1-{[(1-Chloroethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetate
12/21/2006	US20060287249 Of EtO2C CH2 (R)Cgl-Aze-Pab-OH or its salt; high chemical and solid state stability; thrombin inhibitors
12/21/2006	US20060287248 Asymmetric dosing methods
12/21/2006	US20060287247 Halogen-substituted thienyl compounds
12/21/2006	US20060287246 Remedy for eye diseases accompanied by optic nerve injuries
12/21/2006	US20060287245 Anti-tumor agents
12/21/2006	US20060287244 L-Threonine derivatives of high therapeutic index
12/21/2006	US20060287243 Stable pharmaceutical compositions including motilin-like peptides
12/21/2006	US20060287242 chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses; in combination with antidiabetic agent, an anti-obesity agent, an anti-hypertensive agent, an anti-atherosclerotic agent and a lipid-lowering agent
12/21/2006	US20060287241 Combination comprising N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate
12/21/2006	US20060287240 Method of stimulating prosaposin receptor activity
12/21/2006	US20060287239 Biologically active peptides
12/21/2006	US20060287238 Treating a gram negative bacterial infection with a synergistic mixture of a DnaK inhibitor such as pyrrhocoricin or drosocin and another bactericide such as fluoroquinolone, beta-lactam, tetracycline, macrolide, aminoglycoside, glycopeptide, or folic acid synthesis inhibitor family of antibiotics.
12/21/2006	US20060287237 RhoB as a suppressor of cancer cell growth, cell transformation, and metastasis
12/21/2006	US20060287236 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
12/21/2006	US20060287235 Crystallization of IGF-1
12/21/2006	US20060287234 Wound healing
12/21/2006	US20060287233 Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
12/21/2006	US20060287232 Granulysins; effective against Escherichia, Bacillus, and Salmonella
12/21/2006	US20060287231 Therapeutic uses of kallikreins
12/21/2006	US20060287230 Compositions which can be used for regulating the activity of parkin
12/21/2006	US20060287229 Novel CD40 variants
12/21/2006	US20060287228 Expression of active human factor IX in mammary tissue of transgenic animals
12/21/2006	US20060287227 Gonadal function improving agents
12/21/2006	US20060287226 Characterization of a membrane estrogen receptor
12/21/2006	US20060287225 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid
12/21/2006	US20060287224 Glycopegylated erythropoietin formulations
12/21/2006	US20060287223 Remodeling and glycoconjugation of peptides
12/21/2006	US20060287222 Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing
12/21/2006	US20060287221 Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
12/21/2006	US20060287220 Water soluble paclitaxel prodrugs
12/21/2006	US20060286642 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
12/21/2006	US20060286636 VEGF variants
12/21/2006	US20060286635 Albumin fusion proteins
12/21/2006	US20060286632 Genetic engineered apolipoproteins has potent antioxidant activity on phospholipid surfaces; cardiovascular disorders, antiischemic agents, bone disorders, antiinflammatory agents
12/21/2006	US20060286610 Identification of ligands by selective amplification of cells transfected with receptors
12/21/2006	US20060286604 Lectin binding to choroidal neovascularization
12/21/2006	US20060286597 Aortic carboxypeptidase-like polypeptide
12/21/2006	US20060286593 Transforming Growth Factor Alpha HI
12/21/2006	US20060286592 Increased ability to convert 5-fluorocytosine prodrug to its toxic form
12/21/2006	US20060286547 Time-of-addition assay for identifying anti-viral compounds

1 ... 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 ... 3163